Curis, Inc. stock is up 103.1% since 30 days ago. The next earnings date is Mar 11, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 23 December’s closed higher than November. 100% of analysts rate it a buy.
Curis, Inc. engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial. CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation.